We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
Editorial caution Compounded NAD+ injectables are prepared per-patient by licensed compounding pharmacies. This page is an editorial overview, not medical advice or a recommendation. Many peptides have limited human-trial evidence. Always work with a licensed, board-certified clinician.

What it is

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism. Used in IV and injectable forms for energy, cognitive, and longevity protocols.

Mechanism of action

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to cellular energy metabolism, redox reactions, and sirtuin activation. Cellular NAD+ levels decline with age, and supplementing NAD+ is hypothesized to improve mitochondrial function, DNA repair, and metabolic resilience. Direct NAD+ administration (IV or subcutaneous) raises cellular NAD+ levels, though oral precursors (NMN, NR) are also widely used and have more clinical-trial data.

Reported uses

Evidence base

Mixed clinical evidence. Precursors NMN and NR are more studied than NAD+ direct administration.

Regulatory status

Compounded NAD+ injectables are prepared per-patient by licensed compounding pharmacies.

Typical dosing context

Common protocols vary widely:

Dosing in research and clinical-use contexts varies. Specific protocols should always be set by a prescribing clinician, not by patient-direct sources.

Side effects and safety

The most common side effect is the so-called 'NAD+ flush' during IV infusion: chest tightness, flushing, anxiety, and nausea, particularly when infused too rapidly. Slowing the infusion rate resolves this. Subcutaneous NAD+ is associated with significant injection-site stinging. Long-term safety appears reasonable based on the molecule's natural role in metabolism, though high-dose chronic supplementation is not well-studied.

Common stacking protocols

NAD+ is commonly stacked with NMN or NR (oral precursors), CoQ10, and other mitochondrial-support supplements. In longevity-medicine settings, it's combined with metformin, omega-3s, and lifestyle interventions (resistance training, sleep optimization, caloric restriction or time-restricted eating).

How to access NAD+

Most peptides discussed on this page are compounded products requiring a prescription from a licensed clinician. Reputable telehealth peptide programs include physician-led oversight, accredited compounding pharmacies, and clear regulatory framing. For weight-management GLP-1 programs, see our provider reviews.

Frequently asked questions

What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism. Used in IV and injectable forms for energy, cognitive, and longevity protocols.

Is NAD+ FDA-approved?

Compounded NAD+ injectables are prepared per-patient by licensed compounding pharmacies.

What are the typical uses of NAD+?

Uses include: Energy metabolism support, Cognitive performance (research), Longevity stack component. This is research and clinical-use context, not a recommendation. Always work with a licensed clinician.

What is the evidence behind NAD+?

Mixed clinical evidence. Precursors NMN and NR are more studied than NAD+ direct administration.

What is the typical dosing for NAD+?

Reported dosing: 100–500 mg subcutaneous; varies by protocol and tolerance. Actual dosing should always be determined by your prescribing clinician, not by online sources.

Is NAD+ FDA-approved?

No. Compounded NAD+ injectables are prepared per-patient by licensed compounding pharmacies under physician prescription.

How long do the effects last?

Patients commonly report 2–6 weeks of subjective benefit after a loading IV protocol. Effects diminish over time without maintenance dosing.

IV vs subcutaneous vs oral precursors — which is best?

IV produces the highest blood levels but is expensive and time-consuming. Subcutaneous is more convenient but less efficient. Oral NMN/NR is most convenient and has the strongest clinical-trial data, but produces lower peak NAD+ levels.

Related peptides